American Academy of Ophthalmology Meeting
American Academy of Ophthalmology Meeting
November 04, 2018
1 min watch

VIDEO: Santen initiates phase 3 studies of omidenepag for glaucoma

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

CHICAGO — At the American Academy of Ophthalmology meeting here, Ellie Chabi, MD, the therapeutic area head for glaucoma and neuroprotection and the lead for artificial intelligence programs within global biomedical science at Santen, discusses the initiation of two phase 3 clinical trials of omidenepag isopropyl for the treatment of glaucoma and ocular hypertension.